SYBX - Total Utang marang Modal Synlogic

Logo perusahaan publik Synlogic Inc. (SYBX)

Synlogic, Inc. (SYBX) management is currently focusing on optimizing liquidation value and maintaining transparency with investors following a strategic pivot. This price chart confirms this direction, capturing the total debt-to-equity ratio at 0.00. The business relies on the development of synthetic biologics in US laboratories, utilizing the genetic modification of probiotics. However, competitive advantages have been lost due to the freezing of core programs, leaving the company with only cash reserves.

SYBX: Total Utang marang Modal Synlogic Corp 04.07.2022 - 24.01.2026

Rincian analitis perusahaan Synlogic, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Synlogic Inc.|SYBX - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Synlogic|SYBX - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Synlogic|SYBX - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku synlogictx.com|SYBX - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Synlogic, Inc.|SYBX - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Synlogic Inc.|SYBX - Gunggung utang perusahaan|Utang marang nilai buku Synlogic|SYBX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Synlogic|Rasio cepet synlogictx.com
- informasi bathi lan kelipatan valuasi:
SYBX - Penghasilan resik perusahaan
Analisis dhasar perusahaan:Synlogic, Inc.
Barang utama Synlogic

The market assesses Synlogic, Inc. (SYBX) as an entity in the liquidation stage, where a lack of operating leverage leaves the company vulnerable to fixed costs. By analyzing the debt-to-equity ratio, an investor determines the proportion of borrowed funds used to finance assets; an increase in this ratio on the chart signals critical equity dilution and a high risk of insolvency when settling obligations.

Analisis pesaing Synlogic, Inc.

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|Lexicon Pharmaceuticals - Total Utang marang Modal|Utang marang Modal mbxbio.com|ALT (Altimmune) - Rasio Total Utang marang Ekuitas|AARD: Utang Agregat marang Modal|SGMT (Sagimet) - Total Utang marang Modal|Total Utang marang Modal BioAge Labs, Inc|Total Utang marang Modal BMEA|Utang marang Ekuitas QNCX (quincetx.com)|Utang marang Ekuitas Fractyl Health GUTS|vTv Therapeutics, Inc. (VTVT) - Utang marang Modal|ATPC - Utang marang Ekuitas|PLUR: Utang marang Ekuitas|LPCN: Total Utang marang Modal|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Utang marang Ekuitas Organovo Holdings, Inc. ONVO|Koefisien Total Utang marang Modal radiuspharm.com (RDUS)